This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilmink, H. W. Articles by Rabelink, T. J. Search for Related Content PubMed PubMed Citation Articles by Wilmink, H. W. Articles by Rabelink, T. J.

Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function

Hanneke W. Wilmink, MD^*, Jan D. Banga, MD, PhD^*, Michel Hijmering, MD, Willem D. Erkelens, MD, PhD^*, Erik S. G. Stroes, MD, PhD and Ton J. Rabelink, MD, PhD

^* Division of Internal Medicine, University Hospital Utrecht, Utrecht, The Netherlands
Division of Nephrology and Hypertension, University Hospital Utrecht, Utrecht, The Netherlands

View larger version (22K): [in a new window]   Figure 1 Change in postprandial flow-mediated dilation (FMD) compared with preprandial FMD during placebo, quinapril and losartan treatment. The bars represent means with standard errors. Diagonally striped bars = placebo; solid bars = losartan; vertically striped bars = quinapril. #p < 0.05, placebo compared with quinapril treatment. *p < 0.05, losartan compared with quinapril treatment.